NTLA,IQV Stock Price and Quote

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.62
Percentage change -5.14	%

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK ARKG IWM VTI XBI VB VXF IWN VBK IBB

Index	RUT	P/E	-	EPS (ttm)	-5.23	Insider Own	5.95%	Shs Outstand	103.54M	Perf Week	7.40%
Market Cap	1.19B	Forward P/E	-	EPS next Y	-3.86	Insider Trans	-0.17%	Shs Float	97.42M	Perf Month	36.19%
Enterprise Value	810.33M	PEG	-	EPS next Q	-1.03	Inst Own	92.22%	Short Float	30.93%	Perf Quarter	62.92%
Income	-525.91M	P/S	26.22	EPS this Y	20.55%	Inst Trans	2.49%	Short Ratio	6.65	Perf Half Y	-7.50%
Sales	45.57M	P/B	1.53	EPS next Y	7.50%	ROA	-46.84%	Short Interest	30.13M	Perf YTD	-1.07%
Book/sh	7.53	P/C	2.37	EPS next 5Y	31.18%	ROE	-57.92%	52W High	28.18 -59.07%	Perf Year	-48.18%
Cash/sh	4.86	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-61.12%	52W Low	5.90 95.51%	Perf 3Y	-80.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	77.46%	Volatility	7.42% 7.32%	Perf 5Y	-48.71%
Dividend TTM	-	EV/Sales	17.78	EPS Y/Y TTM	2.57%	Oper. Margin	-1173.09%	ATR (14)	0.77	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.90	Sales Y/Y TTM	-13.37%	Profit Margin	-1154.10%	RSI (14)	65.96	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	4.90	EPS Q/Q	1.81%	SMA20	15.67%	Beta	2.30	Target Price	36.64
Payout	-	Debt/Eq	0.15	Sales Q/Q	-42.54%	SMA50	28.26%	Rel Volume	0.82	Prev Close	12.16
Employees	403	LT Debt/Eq	0.10	Earnings	May 08 BMO	SMA200	-0.91%	Avg Volume	4.53M	Price	11.53
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.00% 30.18%	Trades		Volume	3,729,223	Change	-5.14%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144

Show Previous Ratings

Jul-08-25 12:54PM	The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential. (Barchart) +8.49%
Jul-07-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
10:03AM	Loading…
Jun-25-25 10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
Jun-23-25 01:41AM	Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress (Insider Monkey)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily) +6.92%
01:32PM	Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential (Insider Monkey)
05:44AM	FDA clears CSLs swelling disease drug; Regeneron loses 23andMe auction (BioPharma Dive)
Jun-15-25 10:45AM	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.73%
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
09:55AM	Loading…
09:55AM	How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -7.79%
05:56AM	Intellia stock dips following safety event in Phase III gene therapy trial (Clinical Trials Arena)
May-29-25 08:30PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.88%
08:18AM	Intellia stock tumbles on safety concerns (Investing.com)
07:16AM	Intellia filing spurs safety concerns over CRISPR drug (BioPharma Dive)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks) +6.59%
May-18-25 07:25AM	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting (GlobeNewswire)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +5.26%
May-15-25 09:55AM	Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? (Zacks)
May-09-25 12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:12AM	Loading…
03:12AM	Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-08-25 05:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.58%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks)
11:57AM	Intellia Therapeutics Q1 2025 Earnings Preview (Seeking Alpha)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-06-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.10%
08:40AM	CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates (GlobeNewswire)
Apr-30-25 10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +8.17%
Apr-29-25 09:55AM	Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet (Zacks)
Apr-23-25 09:50AM	Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation (PR Newswire)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +9.54%
Apr-11-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +9.45%
Apr-09-25 09:42AM	Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.74%
Apr-04-25 01:42PM	Intellia Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information NTLA (GlobeNewswire)
07:28AM	Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN (Clinical Trials Arena)
Apr-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.62%
12:40PM	IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility (Pharmaceutical Technology)
07:30AM	Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Apr-01-25 12:41PM	Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? (Insider Monkey) -6.40%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 10:10AM	Intellia Focuses on Pipeline Development Amid Stiff Competition (Zacks) -11.90%
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
Mar-26-25 07:30AM	Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-21-25 11:25AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-05-25 09:34AM	Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls (The Fly)
Mar-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-25 06:01AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -7.09%
02:10AM	Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
01:17AM	Q4 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-26-25 08:56PM	Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) -6.95%
Feb-24-25 10:00AM	2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street (Motley Fool) -5.42%
Feb-20-25 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:57AM	Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar? (Zacks)
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates (GlobeNewswire)
Feb-18-25 05:45AM	Intellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA (PR Newswire) +7.76%
Feb-14-25 02:08PM	Intellia Therapeutics (NTLA): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey) +11.00%
09:55AM	Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect? (Zacks)
Feb-06-25 08:10PM	Intellia Therapeutics Inc. (NTLA): Among Cathie Woods Top Stock Picks for 2025 (Insider Monkey)
Feb-04-25 04:01PM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.25%
Jan-23-25 09:14AM	Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema (Clinical Trials Arena)
Jan-22-25 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (GlobeNewswire) +10.76%
05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-13-25 03:00AM	Intellia slashes workforce by 27% to focus on late stage CRISPR candidates (Pharmaceutical Technology)
Jan-11-25 10:20AM	Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital (TipRanks)
07:36AM	Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo (TipRanks)
Jan-10-25 01:30PM	Why Is Intellia Therapeutics Stock Trading Lower On Friday? (Benzinga) -15.14%
03:58AM	Intellia to stop work on rare disease therapy, lay off staff (BioPharma Dive)
Jan-09-25 04:00PM	Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Jan-06-25 07:30AM	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.52%
Dec-30-24 03:51PM	Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-29-24 06:41AM	Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM
Bhanji Muna	Director	Jan 29 '25	Sale	9.97	265	2,642	19,468	Jan 31 04:17 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 03 '25	Sale	12.18	1,372	16,711	45,640	Jan 07 05:23 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '25	Sale	12.18	7,074	86,161	74,497	Jan 07 05:22 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '25	Sale	12.18	9,557	116,404	87,666	Jan 07 05:20 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '25	Sale	12.18	6,502	79,194	59,878	Jan 07 05:20 PM
LEONARD JOHN M	President and CEO	Jan 03 '25	Sale	12.18	26,807	326,509	941,115	Jan 07 05:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '25	Sale	12.18	8,966	109,206	77,388	Jan 07 05:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '25	Sale	12.18	7,422	90,400	64,048	Jan 06 04:16 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 02 '25	Sale	12.03	556	6,689	71,470	Jan 06 04:16 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 02 '24	Sale	19.01	2,012	38,248	47,012	Oct 04 05:29 PM

Dollar change -2.73
Percentage change -1.65	%

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO SPY IVV VTV XLV VOT IBB COWZ

Index	S&P 500	P/E	22.19	EPS (ttm)	7.34	Insider Own	0.87%	Shs Outstand	174.10M	Perf Week	-0.88%
Market Cap	28.16B	Forward P/E	12.57	EPS next Y	12.95	Insider Trans	0.08%	Shs Float	171.50M	Perf Month	1.90%
Enterprise Value	40.80B	PEG	2.54	EPS next Q	2.77	Inst Own	94.64%	Short Float	5.28%	Perf Quarter	3.68%
Income	1.33B	P/S	1.82	EPS this Y	6.25%	Inst Trans	-3.19%	Short Ratio	3.92	Perf Half Y	-19.66%
Sales	15.50B	P/B	4.74	EPS next Y	9.49%	ROA	4.95%	Short Interest	9.05M	Perf YTD	-17.15%
Book/sh	34.33	P/C	15.01	EPS next 5Y	8.72%	ROE	21.65%	52W High	252.88 -35.62%	Perf Year	-23.59%
Cash/sh	10.84	P/FCF	13.02	EPS past 3/5Y	14.76% 50.90%	ROIC	6.93%	52W Low	134.65 20.91%	Perf 3Y	-24.63%
Dividend Est.	-	EV/EBITDA	12.05	Sales past 3/5Y	3.54% 6.79%	Gross Margin	27.52%	Volatility	3.29% 2.81%	Perf 5Y	13.34%
Dividend TTM	-	EV/Sales	2.63	EPS Y/Y TTM	-0.16%	Oper. Margin	14.66%	ATR (14)	4.88	Perf 10Y	123.63%
Dividend Ex-Date	-	Quick Ratio	0.82	Sales Y/Y TTM	2.84%	Profit Margin	8.61%	RSI (14)	58.29	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	0.82	EPS Q/Q	-10.18%	SMA20	1.97%	Beta	1.29	Target Price	184.32
Payout	0.00%	Debt/Eq	2.43	Sales Q/Q	2.43%	SMA50	7.07%	Rel Volume	0.50	Prev Close	165.53
Employees	88000	LT Debt/Eq	2.22	Earnings	Jul 22 BMO	SMA200	-12.47%	Avg Volume	2.31M	Price	162.80
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.54% 1.49%	Trades		Volume	1,156,694	Change	-1.65%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265
Dec-06-22	Initiated	Cowen	Outperform	$251
Nov-17-22	Downgrade	Citigroup	Buy → Neutral	$275 → $245
Aug-25-22	Initiated	Credit Suisse	Outperform	$300
Jul-15-22	Initiated	SVB Leerink	Outperform	$256
May-24-22	Initiated	Guggenheim	Buy	$244
Apr-29-22	Upgrade	Piper Sandler	Neutral → Overweight	$231 → $255

Show Previous Ratings

Jul-11-25 09:45AM	Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:40AM	IQVIA Unveils New Custom AI Agents with NVIDIA (Insider Monkey)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-09-25 11:52AM	Veeva Expands Market Reach Through Targeted Strategic Partnerships (Zacks)
Jul-08-25 12:05PM	VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? (Zacks)
09:34AM	Loading…
09:34AM	Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning (PR Newswire)
05:08AM	What to Expect From IQVIA Holdings' Q2 2025 Earnings Report (Barchart)
Jul-02-25 10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jul-01-25 07:00AM	IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025 (Business Wire)
Jun-30-25 12:39AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-26-25 06:01PM	The Top 5 Analyst Questions From IQVIA's Q1 Earnings Call (StockStory)
10:15AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
Jun-17-25 10:18AM	AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers (PR Newswire)
Jun-16-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV) (StockStory)
09:00AM	Loading…
09:00AM	IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement' (Business Wire)
Jun-11-25 07:00AM	IQVIA Launches New AI Agents for Life Sciences and Healthcare (Business Wire)
Jun-05-25 11:44AM	Doximity Declines 4.4% in a Month: How to Play the Stock Now? (Zacks)
Jun-02-25 04:37PM	IQVIA Announces Pricing of Senior Notes (Business Wire)
08:10AM	IQVIA Announces Offering of Senior Notes (Business Wire)
May-31-25 03:00AM	Ipca Laboratories Ltd (BOM:524494) Q4 2025 Earnings Call Highlights: Strong Domestic Growth and ... (GuruFocus.com)
May-27-25 07:00AM	Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF (PR Newswire)
May-19-25 08:48AM	IQV Q1 Earnings Call: Real-World Evidence Drives Outperformance Amid Sector Uncertainty (StockStory)
05:40AM	IQVIA and SCRI partner to enhance oncology trials (Clinical Trials Arena)
May-16-25 08:00AM	IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials (Business Wire)
May-14-25 04:54PM	S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal (Investopedia) -5.88%
May-13-25 09:16AM	Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends (Zacks)
May-07-25 06:03PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
04:15PM	IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 (Business Wire)
03:12AM	IQVIA Holdings Inc (IQV) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
02:44AM	Loading…
02:44AM	Q1 2025 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 09:00PM	IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
12:33PM	IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y (Zacks)
08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
07:10AM	IQVIA: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports First-Quarter 2025 Results (Business Wire)
May-05-25 03:05AM	After an up and down year, pharmas R&D landscape is shifting again (Pharma Voice)
May-01-25 09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
09:15AM	IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Apr-30-25 10:01AM	RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-25 10:01AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-25 06:50PM	IQVIA Holdings Inc. (IQV): Among Billionaire Israel Englander's Stock Picks with Huge Upside Potential (Insider Monkey)
09:00AM	IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards (Business Wire)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-25-25 09:18AM	HSBC shuffles MedTech stocks, cutting 4, upgrading 2 (Investing.com)
09:16AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-23-25 09:00AM	IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm (Business Wire)
02:38AM	Oakmark U.S. Concentrated Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 04:15PM	IQVIA to Announce First-Quarter 2025 Results on May 6, 2025 (Business Wire)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
12:30AM	Cedar Creek Partners Q1 2025 Results (Seeking Alpha)
Apr-15-25 08:00AM	Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report (Business Wire)
Apr-11-25 12:30PM	Oakmark Global Select Fund Q1 2025 Commentary (Seeking Alpha)
12:20PM	Oakmark Select Fund Q1 2025 Commentary (Seeking Alpha)
Apr-10-25 10:42AM	IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last? (Zacks) -8.79%
Apr-08-25 09:43AM	IQVIA Holdings Inc. (IQV): Among Stocks with Buy Ratings that Hedge Funds Love (Insider Monkey) -5.57%
Apr-01-25 02:27AM	Impax Global Social Leaders Fund Q4 2024 Commentary (Seeking Alpha)
Mar-31-25 03:15PM	Impax Large Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 06:32PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Mar-26-25 10:59AM	Paychex Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y (Zacks)
10:53AM	Here's Why Investors Must Hold IQV Stock in Their Portfolios Now (Zacks)
05:03AM	Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
Mar-24-25 12:35PM	Why IQVIA Holdings Inc. (IQV) is Among the Best Diagnostics Stocks to Invest in Right Now (InsiderMonkey)
Mar-23-25 08:06PM	Tracking William Nygren's Harris Associates Portfolio - Q4 2024 Update (SeekingAlpha)
Mar-21-25 07:40AM	IQVIA Holdings (IQV) Fell on Lowered Guidance (InsiderMonkey)
Mar-20-25 02:50AM	Lazard Global Equity Select Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:09AM	3 Reasons IQV is Risky and 1 Stock to Buy Instead (StockStory)
Mar-10-25 09:00AM	IQVIA recognized as a leader in IDC MarketScapes 2024 assessment for decentralized clinical trial technologies and consulting services (Business Wire)
Mar-04-25 09:00AM	IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials (Business Wire)
Feb-25-25 09:40AM	IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-24-25 09:00AM	IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence (Business Wire)
Feb-21-25 09:00AM	IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025 (Business Wire)
Feb-20-25 10:06AM	IQVIA Releases 2024 Sustainability Report (Business Wire)
Feb-14-25 09:15AM	IQVIA (IQV) International Revenue Performance Explored (Zacks)
Feb-12-25 08:03AM	West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-07-25 03:36PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
02:15AM	IQVIA Holdings Inc (IQV) Q4 2024 Earnings Call Highlights: Record Free Cash Flow and Strategic ... (GuruFocus.com)
02:08AM	Q4 2024 IQVIA Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 09:30AM	Here's What Key Metrics Tell Us About IQVIA (IQV) Q4 Earnings (Zacks)
08:10AM	IQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:08AM	IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars (StockStory)
07:17AM	IQVIA: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance (Business Wire)
Feb-05-25 08:10AM	IQVIA (IQV) Q4 Earnings Report Preview: What To Look For (StockStory)
Feb-04-25 11:00AM	IQVIA named to the Fortune Worlds Most Admired Companies list, ranked No. 1 in its sector for fourth consecutive year (Business Wire)
09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Feb-03-25 09:50AM	IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:16AM	Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jan-30-25 03:55AM	IQVIA Holdings Inc. (IQV): Driving Healthcare Advancements with NVIDIA AI Collaboration (Insider Monkey)
Jan-21-25 04:15PM	IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025 (Business Wire)
Jan-17-25 09:50AM	Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock (Zacks)
Jan-16-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
Jan-15-25 12:10PM	Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:34AM	IQVIA Holdings (IQV) Fell Due to Reduced Near-Term Outlook in its R&D Solutions (Insider Monkey)
Jan-13-25 02:12PM	Why Tech Stocks Are Dropping Monday (Investopedia)
09:00AM	JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic (Pharmaceutical Technology)
09:00AM	IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions (Business Wire)
Dec-23-24 10:19AM	IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains? (Zacks)
08:00AM	Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute (Business Wire)
Dec-14-24 09:00PM	The Drugs Young Bankers Use to Get Through the Dayand Night (The Wall Street Journal)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07 07:03 PM
Sherbet Eric	See Remarks	Aug 27 '24	Sale	246.33	1,300	320,229	19,536	Aug 29 05:02 PM
Sherbet Eric	Officer	Aug 27 '24	Proposed Sale	246.33	1,300	320,229		Aug 27 05:23 PM

NTLA

Intellia Therapeutics Inc

IQV

IQVIA Holdings Inc

Upgrade your FINVIZ experience